Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Orphan Drug Designation Reviews Often Don't Include Regulatory Histories, GAO Says

Executive Summary

Lack of information may mean FDA cannot conduct a thorough review, but HHS argues that products usually are very early in development and therefore don't have a regulatory history to document.
Advertisement

Related Content

US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations
US FDA May Wait Until Late 2019 Before A Cures Hiring Enhancement Is Available
FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff
Orphan Designation Requests To Get Slower Reviews

Topics

Advertisement
UsernamePublicRestriction

Register

PS124356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel